BBO-11818 treatment for adults with KRAS mutant cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 clinical trial evaluates the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in adults with locally advanced unresectable or metastatic solid tumors that have specific KRAS mutations. The study is open-label and multi-center, involving a dose escalation phase and a dose expansion phase, where BBO-11818 is tested alone and in combination with other therapies such as pembrolizumab and platinum chemotherapy. The trial aims to assess the drug's tolerability, pharmacokinetics, and efficacy in treating conditions like non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
* Measurable disease by RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Life expectancy \>24 weeks
* Adequate organ function

Exclusion Criteria:

* Malignancy within the last 2 years as specified in the protocol
* Untreated brain metastases

Other inclusion/exclusion criteria are specified in the protocol.

Where it's running

• The Angeles Clinic and Research Institute - West Los Angeles Office
  Los Angeles, California, United States Recruiting
• University of California Davis
  Sacramento, California, United States Recruiting
• University of California San Diego Moores Cancer Center
  San Diego, California, United States Recruiting
• University of California San Francisco Helen Diller Family Comprehensive Cancer Center
  San Francisco, California, United States Recruiting
• Yale University
  New Haven, Connecticut, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting

Study contacts

• Study coordinator: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
• Email: tbbo11818-101ct.gov@bbotx.com
• Phone: (650) 405-4770

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating BDTX-4933 for patients with specific cancer mutations

  This study is testing a new drug called BDTX-4933 to see if it can help adults with advanced cancers that have certain gene mutations feel better and improve their treatment options.

  Recruiting at 34 sites Phase 1/2 Servier · Gilbert, Arizona and 48 other locations · NCT05786924

• Evaluating BBO-8520 for treating KRAS G12C non-small cell lung cancer

  This study is testing a new drug called BBO-8520 to see if it can safely help adults with a specific type of lung cancer that has a KRAS G12C mutation, both on its own and when combined with another treatment.

  Recruiting at 38 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Birmingham, Alabama and 37 other locations · NCT06343402

• Combining Adagrasib with Stereotactic Radiosurgery for Brain Metastases in Lung Cancer

  This study is testing whether combining a targeted therapy called adagrasib with a type of focused radiation treatment can help people with lung cancer that has spread to the brain feel better.

  Recruiting at 3 sites Phase 2 Hoosier Cancer Research Network · Columbus, Ohio and 2 other locations · NCT06248606

• Evaluating FMC-376 for advanced solid tumors with KRAS G12C mutations

  This study is testing a new drug called FMC-376 to see if it can help people with advanced solid tumors that have a specific KRAS G12C mutation.

  Recruiting at 20 sites Phase 1/2 Frontier Medicines Corporation · La Jolla, California and 25 other locations · NCT06244771

• T cell therapy targeting KRAS G12D in advanced solid tumors

  This trial will test whether autologous T cells engineered to recognize KRAS G12D can help adults with unresectable or metastatic solid tumors who have the matching HLA type.

  Recruiting at 18 sites Phase 1 AstraZeneca · Duarte, California and 17 other locations · NCT06218914

• Evaluating a new CAR T-cell therapy for solid tumors expressing MSLN

  This study is testing a new CAR T-cell therapy to see if it can safely treat adults with solid tumors like colorectal and lung cancer that express a specific protein.

  Recruiting at 12 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 11 other locations · NCT06051695

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.